Side by side
How the two compare across structure, mechanism studied, evidence and regulatory status, based on published research.
PT-141 (Bremelanotide)
Melanocortin-receptor agonist studied in hypoactive sexual desire disorder
View PT-141 (Bremelanotide)| Property | Melanotan II | PT-141 (Bremelanotide) |
|---|---|---|
| Class | Melanocortin agonist | Melanocortin agonist (MC3R/MC4R) |
| Research category | pigmentation and melanocortin signalling | central melanocortin signalling and sexual function |
| Evidence level | Low | High |
| Overall status | Not approved — regulatory warnings issued | Approved (Rx, US) — premenopausal HSDD |
| FDA | Not approved; warnings issued | Approved (Rx) — HSDD |
| EMA | Not approved | Application withdrawn |
| WADA | Check current list | Check current list |
| Mechanism studied | Melanotan II → MC1R–MC5R → Melanogenesis → Central MC4R signalling | PT-141 → MC3R / MC4R → Hypothalamic dopamine → Desire-related signalling |
| Molecular weight | 1,024.2 g/mol | 1,025.2 g/mol |
| Sizes in stock | 10mg | 10mg |
Where the research overlaps
Both compounds are studied within Melanocortin research. Melanotan II is classed as melanocortin agonist, while PT-141 (Bremelanotide) is melanocortin agonist (mc3r/mc4r). Evidence is rated low for Melanotan II and high for PT-141 (Bremelanotide).
For a full write-up, read Melanocortin Peptides: Melanotan, PT-141, Setmelanotide.
FOR RESEARCH USE ONLY.Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.